Stocks · News reference
Metagenomi (NASDAQ:MGX) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.57) by 28.07 percent. This is a 35.19 percent decrease over losses of $(0.54) per share from the
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Wells Fargo analyst Yanan Zhu maintains Metagenomi Therapeutics (NASDAQ:MGX) with a Overweight and lowers the price target from $9 to $7.
Read original at benzingaFiled: 2026-08-10 AccNo: 0001193125-26-342388 Size: 364 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar